Error: Could not add to watchlist. X

Callisto Pharmaceuticals Inc

+ Watchlist
CLSP:US
Acquired
CLSP:US was acquired by SGYP:US
USD
Volume
0
Current P/E Ratio (TTM)
-
Earnings per Share (USD) (TTM)
-0.110
Market Cap (USD)
-
Shares Outstanding (m)
158.966
Price/Sales (TTM)
-
Dividend Indicated Gross Yield
-
Sector
Health Care
Industry
Biotech & Pharma
Sub-Industry
Specialty Pharma

Related Videos

There are currently no related videos for this ticker. Please check back later.
There are currently no news stories for this ticker. Please check back later.
There are currently no press releases for this ticker. Please check back later.
Profile
Callisto Pharmaceuticals Inc. is a drug development company focused on the clinical development of drugs to treat cancer. The company's most advanced drug candidate is Annamycin, an anthracycline for the treatment of relapsed leukemias. Callisto's other products being developed include Atiprimod, for relapsed multiple myeloma and bone resorption.
ADDRESS
420 Lexington Avenue
Suite 1609
New York, NY 10170
United States
PHONE
1-212-297-0010